Inmagene doses first patient in Phase 2b ADAPTIVE trial of IMG-007 for atopic dermatitis; data expected Q4 2026

ImageneBio, Inc.

IMG-007 targets OX40 receptor with silenced ADCC to minimize safety risks and extended half-life for convenient dosing.
ADAPTIVE trial is a global Phase 2b enrolling ~220 patients across three IMG-007 dose arms and placebo.
Primary endpoint: mean percentage change from baseline in EASI score at Week 20.
Topline results from the Phase 2b trial are expected in the fourth quarter of 2026.
Dose-finding study designed to guide optimal dosing for future Phase 3 trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.